

How tapeworms interact with cancers: a mini-review

Manfred Schreiber, Vojtěch Vajs and Petr Horák

Department of Parasitology, Faculty of Science, Charles University Prague, Prague, Czech Republic

ABSTRACT

Cancer is one of the leading causes of death, with an estimated 19.3 million new cases and 10 million deaths worldwide in 2020 alone. Approximately 2.2 million cancer cases are attributed to infectious diseases, according to the World Health Organization (WHO). Despite the apparent involvement of some parasitic helminths (especially trematodes) in cancer induction, there are also records of the potential suppressive effects of helminth infections on cancer. Tapeworms such as *Echinococcus granulosus*, *Taenia crassiceps*, and more seem to have the potential to suppress malignant cell development, although in a few cases the evidence might be contradictory. Our review aims to summarize known epidemiological data on the cancer-helminth co-occurrence in the human population and the interactions of tapeworms with cancers, *i.e.*, proven or hypothetical effects of tapeworms and their products on cancer cells *in vivo* (*i.e.*, in experimental animals) or *in vitro*. The prospect of bioactive tapeworm molecules helping reduce the growth and metastasis of cancer is within the realm of future possibility, although extensive research is yet required due to certain concerns.

Subjects Microbiology, Parasitology, Infectious Diseases, Oncology

Keywords Tapeworm, Cancer, *Taenia*, *Echinococcus*, *Mesocestoides*

INTRODUCTION

Infections with pathogens have been proposed as one of the possible triggers of cancer development (*Colotta et al., 2009*). However, there is also some evidence of cancer suppression due to concurrent infections (*Oikonomopoulou et al., 2013*). Although the main emphasis is on viruses and bacteria (*Schiller & Lowy, 2021; Duong et al., 2019*), eukaryotic parasitic infections cannot be omitted. Parasites such as *Leishmania* spp. (*Caner et al., 2020; Al-Kamel, 2017*), *Trypanosoma cruzi* (*Ribeiro Franco et al., 2023*), and *Toxoplasma gondii* (*Baird et al., 2013*) are hypothesized to be able to influence cancer development; their attenuated forms or products show a promising anti-cancer effect *in vivo/in vitro*. Regarding helminths as multicellular parasites, the research of cancer-pathogen interactions is still in its infancy.

Helminths are prevalent parasites in humans, mainly in tropical and subtropical countries. For example, it is estimated, that the number of people infected by soil-transmitted helminths reaches up to 1.5 billion (*Fong & Chan, 2022*). On the other hand, in high-income global north countries with high hygiene standards, the number of human infections by helminths is usually low. The latter situation might have

Submitted 28 November 2023

Accepted 14 March 2024

Published 29 March 2024

Corresponding author

Petr Horák,

petr.horak@natur.cuni.cz

Academic editor

Kenneth De Baets

Additional Information and
Declarations can be found on
page 10

DOI 10.7717/peerj.17196

© Copyright

2024 Schreiber et al.

Distributed under

Creative Commons CC-BY 4.0

OPEN ACCESS

unanticipated consequences: the absence of certain pathogens, including helminths, may result in a more frequent occurrence of other (mainly autoimmune) diseases, which are rare in helminth-rich communities (“hygienic hypothesis” and “old friend hypothesis” (Strachan *et al.*, 2000; Rook, 2010)). In other words, helminths in humans influence the immune system by exposing it to many antigens (in a sort of training) and by producing bioactive molecules that modify specific immune reactions. Therefore, helminths are well pre-adapted to form a tight association with their human hosts.

Not only is the immune system influenced by helminths (in many cases, modified T-helper cell 2 (Th2) and regulatory T cell (Treg) responses are triggered in chronic helminthoses (Maizels & Yazdanbakhsh, 2003; Hewitson, Grainger & Maizels, 2009)), but these infections may impact other types of human diseases, namely cancers. Some helminths are known as proven cancerogenic agents (*Clonorchis sinensis*, *Opisthorchis viverrini*, *Schistosoma haematobium*; these flukes belong to group 1 human carcinogens as of 2012 (Bouvard *et al.*, 2009)). Human cancers caused by helminth infection may include cholangiocarcinoma, colorectal cancer, hepatocellular carcinoma, urinary bladder cancer, and other malignancies (e.g., Scholte, Pascoal-Xavier & Nahum, 2018; Correia da Costa *et al.*, 2021; Wu *et al.*, 2022). On the other hand, some helminths display possible cancer-suppressing ability which has been indicated by some epidemiological surveys for humans, animal experiments or *in vitro* (see below for details). For example, in the mouse model, *Trichinella spiralis*, as a representative of nematodes, has been repeatedly associated with cancer suppression (Wang *et al.*, 2009; Kang *et al.*, 2013; Vasilev *et al.*, 2015). In the human population, some epidemiological data support this view. For example, the decline of *Ascaris lumbricoides* prevalence in Korea during 1971–1992 has been followed by a remarkable increase in breast cancer incidence during 1992–2013 (Yousefi *et al.*, 2023) and the mean survival time of patients with adult T-cell leukemia was longer if they had a concurrent infection with *Strongyloides stercoralis* (Plumelle *et al.*, 1997). The first possible cancer-suppressing effect of a flatworm has been postulated with *Echinococcus granulosus*, a highly pathogenic cestode responsible for human cystic echinococcosis (van Knapen, 1980).

Regarding tapeworms (Cestoda), their life cycles contain one or two intermediate hosts and a final host. Based on the tapeworm species, humans can harbor either larval or adult cestodes (or both, like in the case of *Taenia solium*). The adults live exclusively in the digestive tract (the intestine), whereas larval stages invade various tissues/organs and may be life-threatening (larvae of *Echinococcus* spp., *T. solium*, etc.). Although some experimental data with laboratory rodents (see below) show that the presence of tapeworm larvae or their products could negatively influence cancer cells, it is ethically and practically disputable to infect cancer-bearing patients with living worms, which cause other pathologies. In this regard, the situation substantially differs from some other helminth treatment procedures considered in the recent years (e.g., the curative application of *Trichuris suis* in people with inflammatory bowel disease (Huang *et al.*, 2018)). Fortunately, state-of-the-art parasitology offers advanced molecular tools to characterize and produce parasite effector molecules *in vitro*. Such molecules can potentially affect




Figure 1 Anticipated mechanisms of tapeworm effects on cancer. Although the pathways by which tapeworms suppress tumor development are unknown in many cases, several proposed mechanisms exist. The worms could directly damage cancer cells through their products or indirectly by influencing the host immune system. The latter may occur either due to the parasite exhibiting the same antigen epitopes as cancer cells or because its products affect various immune system cells, directly killing cancer cells or activating other immune cells. Of course, some not yet recognized processes/interactions might also be involved. DCs—dendritic cells, NK—natural killer cells, CD8+—CD8+ T cells, EgKI1-Kunitz-type protease inhibitor produced by *E. granulosus*. [Full-size !\[\]\(ba1b80118482ccef74a5d718ca4d7242_img.jpg\) DOI: 10.7717/peerj.17196/fig-1](https://doi.org/10.7717/peerj.17196/fig-1)

cancer cells directly (tapeworm molecules interfere with the cancer cell activities) or indirectly (stimulation of the immune system to intervene in cancer growth/survival) (Fig. 1).

Our review aims at the up-to-date knowledge of *in vivo* (using experimental animals)/*in vitro* interactions between tapeworms/tapeworm products and cancers, reflecting, for particular helminth species and infections caused by them, the circumstantial epidemiological pieces of evidence, *in situ* observations as well as experimental data using the tools of cell biology.

SURVEY METHODOLOGY

Our study includes articles on tapeworms and their effect on cancers. Due to the complexity of helminth-influenced immune responses, we included only studies discussing the connection between tapeworm-activated immune systems and cancer. The Web of Science and PubMed databases were used for the literature search. The following keywords and their combinations were used: “Tapeworm”, “Cestod”, “Cancer”, “*Taenia*”, “*Echinococcus*”, “*Mesocostoides*”, and “*Hymenolepis*”; the alternative terms like “Echinococcosis” or “Hydatidosis” were also considered. The articles were checked for




Figure 2 Flowchart of how the literature was selected. Full-size [DOI: 10.7717/peerj.17196/fig-2](https://doi.org/10.7717/peerj.17196/fig-2)

their suitability for this review. The non-relevant articles (covering, *e.g.*, anthelmintic drugs and their effect on cancer, and immune responses triggered by helminth infections with no relation to cancer) were excluded. On the other hand, all articles describing any cestode-cancer and cestode-immune system-cancer interactions were selected and analyzed. For example, the combination “cancer” AND “tapeworm” (Web of Science) produced 101 results, and 39 were found reliable and used in our review. Altogether, we included 44 papers on cestode-cancer interactions in our review (Fig. 2).

Particular tapeworm species and cancer

Echinococcus granulosus

Several epidemiological studies indicated a possible influence of *E. granulosus* cysts on cancers in humans. [Akgül et al. \(2003\)](#) observed a reduced cancer prevalence in *E. granulosus* patients in a retrospective study in Turkey, and the authors hypothesized that the infection could suppress cancer development. Although there is also a retrospective study from Cyprus with results to the contrary ([Oikonomopoulou et al., 2016](#)). However, the latter involved patients with previously treated cystic echinococcosis and not an active infection at the time of cancer diagnosis ([Gundogdu, Saylam & Tez, 2017](#)). Another retrospective study showed that patients with hepatocarcinoma co-infected with *E. granulosus* had a longer survival time than those without this tapeworm ([Bo et al., 2020](#)).

Recently, the interactions of *E. granulosus* with host immunity and cancers have been thoroughly reviewed by [Guan et al. \(2019\)](#). As to the experiments with living larvae, the

promising cancer-suppressing effects were tested on fibrosarcoma cells *in vitro*. Co-cultivation with tapeworm larvae led to the inhibition of proliferation and reduced viability of the cells (Darani et al., 2012). Additionally, *in vivo*, laboratory rats infected with *E. granulosus* protoscoleces showed significant suppression of chemically-induced mammary carcinoma development (Altun et al., 2015).

Due to the pathogenicity of this tapeworm, the research has frequently shifted toward selected components/fractions and identified molecules of *E. granulosus* larvae. Injection of larval cystic fluid into mice, which were then inoculated with B16F10 melanoma cells, resulted in tumor growth inhibition (Darani et al., 2016); the same happened if the cystic fluid was applied to mice with already developed melanomas (Rad et al., 2018). Regarding particular components, the 78 kDa fraction was confirmed to produce a similar effect in mice (Rad et al., 2018). As for other types of cancers, the cystic fluid triggered the inhibition of tumor growth in mice injected subcutaneously with CT27 colon carcinoma cells; the survival time of mice significantly improved (Berriel et al., 2013). Similar results were also observed using a lung cancer line (Berriel et al., 2021).

Under *in vitro* conditions, apoptosis of breast cancer cells was induced in the presence of *E. granulosus* larval cystic fluid. This effect was also observed using glycoprotein fractions and one 78 kDa fraction of the cystic fluid (Daneshpour et al., 2019). As for melanomas, the miRNA-365 component of the cystic fluid can induce apoptosis in the A375 melanoma cell line (Mohammadi et al., 2021); however, this conflicts with the results from Gao, Zhang & Huang (2018), who described inhibition of apoptosis using the complete cystic fluid.

Regarding particular bioactive molecules, EgKI-1 is a Kunitz-type protease inhibitor produced by *E. granulosus* (Ranasinghe et al., 2015). Culturing several human tumor cell lines *in vitro* in the presence of recombinant EgKI-1 inhibited their growth and hindered the ability of these cells to migrate, while not affecting the growth of normal cells. EgKI-1 was also able to induce apoptosis in human breast cancer cells. Applying this protease inhibitor to mice with the same breast cancer cell line also suppressed tumor growth *in vivo* (Ranasinghe et al., 2018). Another interesting Kunitz-type protease inhibitor from *E. granulosus* is Kunitz4 (EgKI-4). Peptides derived from Kunitz4 have been shown to induce apoptosis and inhibit proliferation in cancer cell lines *in vitro* due to being an ion channel blocker (Rashno et al., 2023).

Besides these direct effects of tapeworm products, immune-mediated processes may play a significant role. One of the critical processes in activating anti-tumor immunity is the recognition of antigens on the surface of tumor cells. Similarities between the antigens in the cystic fluid of *E. granulosus* and those produced by lung cancer cells were described (Yong, Heath & Savage, 1979). One of these antigens is the O-glycosylated Tn antigen (α N-acetylgalactosamine-O-serine/-threonine), expressed by larvae and adults of *E. granulosus*, which has also been detected in the sera of patients with cystic echinococcosis. This glycoprotein is abundant on the surface of many tumor cells, including lung, breast, and pancreatic cancers (Springer, 1997). Antibodies raised against *E. granulosus* larvae reacted with tumor cell excretory-secretory products. Analogously, the same cross-reactivity was observed with sera from breast cancer patients and *E. granulosus*

larval cyst antigens. Thus, it is thought that this antibody response against the Tn antigen could activate anti-tumor immunity (Alvarez Errico *et al.*, 2001). Sera from breast cancer patients also responded to a non-glycosylated 27 kDa molecule isolated from *E. granulosus* larval cysts (Sharafi *et al.*, 2016). Moreover, murine antibodies raised against *E. granulosus* cystic fluid recognize some antigens on CT27 colon carcinoma cells. Thus, the cross-reactivity of antigens could inhibit CT27 tumor growth in mice treated with *E. granulosus* cystic fluid (Berriel *et al.*, 2013). An antibody cross-reaction could also explain the cytotoxic effect of serum from echinococcosis patients on human lung cancer cells *in vitro* (Karadayi *et al.*, 2013). Regarding the cross-reactivity phenomenon, the cancer cell-derived antigens are believed to be poorly immunogenic. On the other hand, the parasite antigens are usually highly immunogenic; therefore, in the case of similar motifs shared between cancer and parasite, the cross-reacting antibodies might represent a path for cancer immunotherapy in the future (Ubillos *et al.*, 2007; Yousefi *et al.*, 2023).

Echinococcus granulosus may also affect specific groups of immune cells associated with anti-cancer immunity. For example, the application of a mucin-like peptide isolated from *E. granulosus* larvae (Egmuc) led to an increase in the number of activated NK cells in the mouse spleen, with NK cells being an essential component of anti-tumor immunity and used in tumor immunotherapy (Salagianni *et al.*, 2012); activated NK1.1 cells probably also caused reduced tumor development in mice treated with *E. granulosus* cystic fluid (Berriel *et al.*, 2021). Splenocytes isolated from Egmuc-treated mice had a cytotoxic effect on pancreatic tumor cells of the Panc02 line when cultured *in vitro* (Noya *et al.*, 2013). In addition, EgKI-1 produced by *E. granulosus* inhibits neutrophil chemotaxis (Ranasinghe *et al.*, 2015), and antigen B isolated from the cystic fluid of *E. granulosus* has the same effect (Shepherd, Aitken & McManus, 1991; Mamuti *et al.*, 2006). Neutrophils are involved in the host immune response against *E. granulosus* infection (Zhang, Ross & McManus, 2008). They are also associated with the progression, metastasis, and angiogenesis in the tumor microenvironment (Coffelt, Wellenstein & De Visser, 2016). Thus, inhibition of neutrophil chemotaxis mediated by *E. granulosus* products could contribute to the observed anti-tumor effect of this tapeworm.

Although most of the research points to the cancer-suppressing effect of *E. granulosus*, there are also studies opposing this fact. For example, Turhan *et al.* (2015) postulate that *E. granulosus* infection in mice enhances the development of liver metastases with 4T1 cell line breast tumors. Furthermore, the co-cultivation of HepG2 cells with *E. granulosus* protoscoleces led to increased proliferation *in vitro* and larger subcutaneous tumors in mice (Yasen *et al.*, 2021). It appears, then, that the products do not affect all cancer cell lines equally. Therefore, the story of *E. granulosus*-derived components participating in the fight against cancer must be taken with caution, and further studies are welcome.

Taenia crassiceps

The tapeworm *T. crassiceps* is well known for its ability to rapidly reproduce in the intermediate host, making it a suitable laboratory model using rodents (Willms & Zurabian, 2010). As for humans, infections by larval stages are quite rare and appear to be linked with immunocompromised patients (Heldwein *et al.*, 2006); therefore, there is no

epidemiological data on tapeworm-cancer associations in humans. The direct effect of *T. crassiceps* cysticerci on cancer was investigated in the experimental model of ulcerative colitis-associated carcinoma (CAC). Infection of mice with *T. crassiceps* cysticerci before the application of the carcinogen resulted in fewer tumors (León-Cabrera et al., 2014). Expression of both β -catenin, which plays a role in cell proliferation, and CXCR2, a neutrophil chemokine receptor (interleukin 8 receptor β), have been suppressed in CAC mice infected with *T. crassiceps*; elevated levels of these markers are associated with bowel cancer (Ou et al., 2019). An increase in the macrophage population and locally high levels of IL-4 in the intestinal tissue have also been observed during *T. crassiceps* infection (Ledesma-Soto et al., 2015). Excretory-secretory products of *T. crassiceps* larvae display a similar anti-carcinogenic effect when administered post-CAC induction (Callejas et al., 2019). Since the development of CAC is associated with an inflammatory environment, the tumor-suppressing effect of *T. crassiceps* could be linked with its ability to shift the immune response towards the anti-inflammatory Th2 (Terrazas et al., 1998).

GK-1, a peptide isolated from *T. crassiceps* larvae, could contribute to the anti-tumor effect. The synthetically generated GK-1 administered to breast cancer-bearing mice induced increased necrosis of tumors and reduction of lung metastases (Torres-García et al., 2017); the same effects were observed in mice with subcutaneous B16F10 melanomas (Pérez-Torres et al., 2013).

GK-1 also increases the efficiency of the dendritic cell mouse vaccination system to activate specific anti-tumor T cells. The most substantial effect on melanoma tumor reduction and mouse survival was observed when dendritic cells were pre-stimulated with GK-1 (Piñón-Zárate et al., 2014). The anti-tumor effect was strengthened by combining GK-1 with an anti-PDL1 (“programmed cell death ligand 1”) antibody. PDL1 can be expressed on the surface of tumor cells (Keir et al., 2008), thereby reducing the cytotoxic effect of T cells on tumor cells by binding their receptor and inducing T cell apoptosis (Iwai et al., 2002). Mice treated with GK-1 and anti-PDL1 antibodies developed smaller B16F10 subcutaneous tumors and had their survival improved (Vera-Aguilera et al., 2017). GK-1 alone applied to mice with established B16F10 melanomas suppressed tumor growth. There was also an increase in the population of tumor-infiltrating CD8+ T cells, with decreased PD1 (receptor for PDL1) expression in these CD8+ T cells. Reducing PD1 expression in activated lymphocytes could increase their cytotoxic activity and lead to the observed suppression of tumor growth (Rodríguez-Rodríguez et al., 2020).

Other tapeworms

Hymenolepis nana is another tapeworm that has been observed to inhibit tumor growth. Although this is the most prevalent tapeworm in the human intestine (adult forms), it is scarce as an extraintestinal larval infection in humans (Olson et al., 2003). In a carcinogen-induced skin tumor model, mice pre-infected with *H. nana* developed fewer tumors compared to controls. Furthermore, infected mice showed an increased number of eosinophils and neutrophils; the increased number of eosinophils could reduce the number of tumors (Ramos-Martínez et al., 2019). On the other hand, the related species, *Hymenolepis diminuta*, did not affect the C3(1)-TAg mouse model of breast cancer (Sauer et al., 2021).

Table 1 Summary of tapeworm products suppressing cancer development.

Tapeworm	Developmental stage/Antigen	Assay	Effect	Cancer type (Abbreviations of cancer cell lines)	References
<i>E. granulosus</i>	Living larvae	<i>In vitro</i>	Cell lysis, proliferation inhibition	WEHI-164 fibrosarcoma, BHK fibroblasts	Darani et al. (2012)
	Living larvae	Rats	Reduced tumor growth	DMBA-induced breast cancer	Altun et al. (2015)
	Cystic fluid	Mice	Reduced tumor growth, NK cell activation	B16F10 melanoma, CT27 colon carcinoma, LL/2 lung cancer	Darani et al. (2016) , Berriel et al. (2021)
	78 kDa fraction of cystic fluid	<i>In vitro</i>	Increased apoptosis	4T1 breast cancer	Daneshpour et al. (2019)
	78 kDa fraction of cystic fluid	Mice	Reduced tumor growth	B16F10 melanoma	Rad et al. (2018)
	miRNA-365 cystic fluid component	<i>In vitro</i>	Increased apoptosis	A375 melanoma	Mohammadi et al. (2021)
	EgKI-1	Mice	Inhibited neutrophil chemotaxis	MDA-MB-231 breast cancer	Ranasinghe et al. (2018)
	EgKI-1	<i>In vitro</i>	Inhibited proliferation and migration	MDA-MB-231, HeLa cell line	Ranasinghe et al. (2018)
	EgKI-4 (Kunitz4)	<i>In vitro</i>	Increased apoptosis, inhibited proliferation	HT29 colorectal adenocarcinoma, HepG2 liver cancer	Rashno et al. (2023)
<i>T. crassiceps</i>	Egmuc	Mice	Increased cytotoxic effect of splenocytes	Panc02 pancreatic cancer	Noya et al. (2013)
	Living larvae/ESP	Mice	Reduced tumor growth, Th2 polarization, reduction of b-catenin and CXCR2 expression	Colitis-associated carcinoma	León-Cabrera et al. (2014) , Callejas et al. (2019)
<i>H. nana</i>	GK-1	Mice	Reduced tumor growth and metastases, increased numbers of cytotoxic CD8+ T lymphocytes	4T1 breast cancer, B16F10 melanoma	Torres-García et al. (2017) , Rodríguez-Rodríguez et al. (2020)
	Living mature tapeworms	Mice	Reduced tumor growth, increased numbers of eosinophils and neutrophils	7,12 dimethylbenz-anthracene-induced skin cancer	Ramos-Martínez et al. (2019)
<i>M. corti</i>	Living larvae	Mice/ <i>in vitro</i>	Activated eosinophil-induced apoptosis	A20 lymphoma	Costain et al. (2001)
<i>T. solium</i>	Calreticulin	<i>In vitro</i>	Reduced ability to form colonies, reduced viability	MCF7, SKOV3 adenocarcinoma	Schcolnik-Cabrera et al. (2020)

Note:

ESP, excretory-secretory products; GK-1, peptide isolated from *T. crassiceps* larvae; EgKI-1, Kunitz-type protease inhibitor produced by *E. granulosus*; EgKI-4 (Kunitz4), Kunitz-type protease inhibitor produced by *E. granulosus*; Egmuc, mucin-like peptide isolated from *E. granulosus* larvae.

Although the effect of *Mesocestoides corti* on cancer was never directly studied, in one case, *M. corti* infection was used in mice to induce eosinophilia. Such activated eosinophils were isolated and stimulated apoptosis in a lymphoma cell line *in vitro* ([Costain et al., 2001](#)). Furthermore, *M. corti*, similar to *E. granulosus*, expresses the Tn antigen found on some cancer cells ([Ubillos et al., 2007](#); [Medeiros et al., 2008](#)). To support the data mentioned above, our experimental results with *M. corti* and *T. crassiceps* show that

tapeworm larvae inhibit melanoma development in experimental mice ([Schreiber et al., 2024](#)).

Infection with *Taenia solium* is more often associated with cancer promotion ([Del Brutto et al., 1997](#); [Herrera et al., 2000](#)); however, a recombinant form of calreticulin isolated from *T. solium* larvae has been shown to reduce the viability of the MCF-7 breast cancer cell line and the ability to form colonies of the SKOV-3 ovarian cancer cell line *in vitro* ([Schcolnik-Cabrera et al., 2020](#)).

CONCLUSIONS

The interaction between tapeworms and cancers has yet to be fully understood. Based on the summary above, the tapeworms (like all other parasites/pathogens) might exhibit a “dual” role concerning particular cancer type development and parasite-cancer interaction. The limitations are based on a few tapeworm models used to test their effects on cancers and the unbalanced amount of data available (often, only *E. granulosus* has been studied in this regard, and any experimental data with humans are missing; only epidemiological surveys could indicate the interaction). Moreover, the observed effects are frequently related to a specific tapeworm-cancer combination. In some cases, particular authors have obtained contradictory effects (e.g., inhibition *vs.* stimulation of cancer growth by *E. granulosus* ([Wang et al., 2009](#); [Noya et al., 2013](#))).

Our review shows that mainly tapeworm larvae invading tissues were studied in the past. The adult worms in the intestine were usually ignored (although they could influence the gut microbiota composition and general immune status ([Walusimbi et al., 2023](#))). If some tapeworm larvae/larval products lead to the reduction or elimination of primary cancers and metastases, the molecular mechanisms behind the process should be studied and tested for their potential medical application (as a preventive or curative tool). Such activities are currently linked to the basic research stage (*in vivo* experiments with animals or *in vitro* tests with cancer cells); we did not record any clinical trial using tapeworms as an effector tool to suppress cancer.

Tapeworm larvae are generally pathogenic, administering a cocktail of bioactive tapeworm molecules (see [Table 1](#) for example) seems like a more relevant approach. At least three groups of such molecules can be considered: (a) In some combinations, tapeworm larvae and cancers share antigenic epitopes (frequently glycans) that can cross-react with specific antibodies. This way, timely immunization with tapeworm antigens (which seem more immunogenic than the shared cancer antigens ([Berriel et al., 2021](#); [Yousefi et al., 2023](#))) could protect against developing cancers in specific combinations. (b) Some tapeworm products could boost various (innate or adaptive) components of the immune system, which could then eliminate the cancer cells. The most probable mechanism is the activation of tumor-infiltrating NK cells or specific anti-tumor CD8+ T cells ([Rodríguez-Rodríguez et al., 2020](#); [Berriel et al., 2021](#)). (c) It seems that some parasite-derived molecules directly affect cancer cells (their activities, including replication, migration, invasiveness, apoptosis, *etc.*), and they are effective in the *in vivo* system ([Ranasinghe et al., 2015, 2018](#)). In all these possible effects of tapeworm products, the mode of administration into the host body will play a crucial role and must be tested.

To conclude, the prospect of bioactive tapeworm molecules helping reduce the growth and metastasis of cancer is within the realm of future possibility, although extensive research is yet required due to certain concerns, which we already mentioned above. Furthermore, these tapeworms may cause life-threatening tissue helminthoses, besides being the source of substances with potential anti-cancer properties. In order to avoid infection with living parasites by utilizing said molecules directly, the effectors' production, their formulation, and administration needs to be managed first, in order to test the desired effects, while the precise mode of action of these compounds must also be characterized.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This research is currently supported by the Czech Science Foundation (21-28946S), the European Regional Development Fund and Ministry of Education, Youth and Sports of the Czech Republic (CZ.02.1.01/0.0/0.0/16_019/0000759), the Charles University Grant Agency (B-BIO 283823), and the Charles University institutional support (Cooperatio Biology, UNCE/SCI/012-204072/2018, UNCE24/SCI/011, and SVV 260678/2023). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:

Czech Science Foundation: 21-28946S.

European Regional Development Fund and Ministry of Education, Youth and Sports of the Czech Republic: CZ.02.1.01/0.0/0.0/16_019/0000759.

Charles University Grant Agency: B-BIO 283823.

Charles University institutional support: Cooperatio Biology, UNCE/SCI/012-204072/2018, UNCE24/SCI/011, and SVV 260678/2023.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- Manfred Schreiber conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
- Vojtěch Vajs performed the experiments, prepared figures and/or tables, and approved the final draft.
- Petr Horák conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

Data Availability

The following information was supplied regarding data availability:

This is a literature review.

REFERENCES

- Akgül H, Tez M, Ünal AE, Keşkek M, Sayek I, Özçelik T. 2003. Echinococcus against cancer: why not? *Cancer* **98**(9):1998–1999 DOI [10.1002/cncr.11755](https://doi.org/10.1002/cncr.11755).
- Al-Kamel MAN. 2017. Leishmaniasis and malignancy: a review and perspective. *Clinical Skin Cancer* **2**(1–2):54–58 DOI [10.1016/j.clsc.2017.10.003](https://doi.org/10.1016/j.clsc.2017.10.003).
- Altun A, Saraydin SU, Soylu S, Inan DS, Yasti C, Ozdenkaya Y, Koksal B, Duger C, Isbir C, Turan M. 2015. Chemopreventive effects of hydatid disease on experimental breast cancer. *Asian Pacific Journal of Cancer Prevention* **16**(4):1391–1395 DOI [10.7314/APJCP.2015.16.4.1391](https://doi.org/10.7314/APJCP.2015.16.4.1391).
- Alvarez Errico D, Medeiros A, Míguez M, Casaravilla C, Malgor R, Carmona C, Nieto A, Osinaga E. 2001. O-glycosylation in *Echinococcus granulosus*: identification and characterization of the carcinoma-associated Tn antigen. *Experimental Parasitology* **98**(2):100–109 DOI [10.1006/expr.2001.4620](https://doi.org/10.1006/expr.2001.4620).
- Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S. 2013. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated *Toxoplasma gondii* protects against rechallenge. *The Journal of Immunology* **190**(1):469–478 DOI [10.4049/jimmunol.1201209](https://doi.org/10.4049/jimmunol.1201209).
- Berriel E, Freire T, Chiale C, Rodríguez E, Morón G, Fernández-Graña G, Crispo M, Berois N, Osinaga E. 2021. Human hydatid cyst fluid-induced therapeutic anti-cancer immune responses via NK1.1+ cell activation in mice. *Cancer Immunology, Immunotherapy* **70**(12):3617–3627 DOI [10.1007/s00262-021-02948-x](https://doi.org/10.1007/s00262-021-02948-x).
- Berriel E, Russo S, Monin L, Festari MF, Berois N, Fernández G, Freire T, Osinaga E. 2013. Antitumor activity of human hydatid cyst fluid in a murine model of colon cancer. *The Scientific World Journal* **2013**(5):230176 DOI [10.1155/2013/230176](https://doi.org/10.1155/2013/230176).
- Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group. 2009. A review of human carcinogens—Part B: biological agents. *Lancet Oncology* **10**(4):321–322 DOI [10.1016/s1470-2045\(09\)70096-8](https://doi.org/10.1016/s1470-2045(09)70096-8).
- Bo R, Yasen A, Shao Y, Zhang W, Lin R, Jiang T, Wen H, Xiao H, Aji T. 2020. Co-existence of hepatocellular carcinoma and cystic echinococcosis. *Infectious Agents and Cancer* **15**(1):1–8 DOI [10.1186/s13027-020-0275-0](https://doi.org/10.1186/s13027-020-0275-0).
- Callejas BE, Mendoza-Rodríguez MG, Villamar-Cruz O, Reyes-Martínez S, Sánchez-Barrera CA, Rodríguez-Sosa M, Delgado-Buenrostro NL, Martínez-Saucedo D, Chirino YI, León-Cabrera SA, Pérez-Plasencia C, Vaca-Paniagua F, Arias-Romero LE, Terrazas LI. 2019. Helminth-derived molecules inhibit colitis-associated colon cancer development through NF-κB and STAT3 regulation. *International Journal of Cancer* **145**(11):3126–3139 DOI [10.1002/ijc.32626](https://doi.org/10.1002/ijc.32626).
- Caner A, Sadiqova A, Erdoğan A, Dünya N, Nalbantsoy A, Oltulu F, Toz S, Yiğittürk G, Özkök E, Gunduz C, Ozbel Y, Haydaroglu A. 2020. Targeting of antitumor immune responses with live-attenuated Leishmania strains in breast cancer model. *Breast Cancer* **27**(6):1082–1095 DOI [10.1007/s12282-020-01112-0](https://doi.org/10.1007/s12282-020-01112-0).
- Coffelt SB, Wellenstein MD, De Visser KE. 2016. Neutrophils in cancer: neutral no more. *Nature Reviews Cancer* **16**(6):431–446 DOI [10.1038/nrc.2016.52](https://doi.org/10.1038/nrc.2016.52).
- Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. 2009. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis* **30**(7):1073–1081 DOI [10.1093/carcin/bgp127](https://doi.org/10.1093/carcin/bgp127).

- Correia da Costa J, Gouveia M, Rinaldi G, Brindley PJ, Santos J, Santos L. 2021. Control strategies for carcinogenic-associated helminthiasis: an integrated overview. *Frontiers in Cellular and Infection Microbiology* 11:626672 DOI 10.3389/fcimb.2021.626672.
- Costain DJ, Guha AK, Liwski RS, Lee TDG. 2001. Murine hypodense eosinophils induce tumour cell apoptosis by a granzyme B-dependent mechanism. *Cancer Immunology, Immunotherapy* 50(6):293–299 DOI 10.1007/PL00006690.
- Daneshpour S, Kefayat A, Mofid M, Rostami Rad S, Yousofi Darani H. 2019. Effect of hydatid cyst fluid antigens on induction of apoptosis on breast cancer cells. *Advanced Biomedical Research* 8(1):27 DOI 10.4103/abr.abr_220_18.
- Darani H, Sharafi S, Mokarian F, Yousefi M, Sharafi S, Jafari R. 2016. Therapeutic effect of hydatid cyst liquid on melanoma tumor growth in mouse model. *British Journal of Medicine and Medical Research* 18(2):1–7 DOI 10.9734/BJMMR/2016/27220.
- Darani H, Soozangar N, Khorami S, Taji F, Yousofi M, Shirzad H. 2012. Hydatid cyst protoscolices induce cell death in WEHI-164 fibrosarcoma cells and inhibit the proliferation of baby hamster kidney fibroblasts *in vitro*. *Journal of Parasitology Research* 2012(3):304183 DOI 10.1155/2012/304183.
- Del Brutto OH, Castillo PR, Mena IX, Freire AX. 1997. Neurocysticercosis among patients with cerebral gliomas. *Archives of Neurology* 54(9):1125–1128 DOI 10.1001/archneur.1997.00550210057013.
- Duong MTQ, Qin Y, You SH, Min JJ. 2019. Bacteria-cancer interactions: bacteria-based cancer therapy. *Experimental & Molecular Medicine* 51(12):1–15 DOI 10.1038/s12276-019-0297-0.
- Fong D, Chan MM. 2022. 20: Soil-Transmitted helminth infections. In: *Human Parasites*, 502–527 DOI 10.1142/9789811236273_0020.
- Gao X-Y, Zhang G-H, Huang L. 2018. Modulation of human melanoma cell proliferation and apoptosis by hydatid cyst fluid of *Echinococcus granulosus*. *OncoTargets and Therapy* 11:1447–1456 DOI 10.2147/OTT.
- Guan W, Zhang X, Wang X, Lu S, Yin J, Zhang J. 2019. Employing parasite against cancer: a lesson from the canine tapeworm *Echinococcus granulosus*. *Frontiers in Pharmacology* 10:1137 DOI 10.3389/fphar.2019.01137.
- Gundogdu SB, Saylam B, Tez M. 2017. Cyst hydatid and cancer: the myth continues. *Clinical Chemistry and Laboratory Medicine* 55(7):e150–e151 DOI 10.1515/cclm-2016-0626.
- Heldwein K, Biedermann HG, Hamperl WD, Bretzel G, Löscher T, Laregina D, Frosch M, Büttner DW, Tappe D. 2006. Subcutaneous *Taenia crassiceps* infection in a patient with non-Hodgkin's lymphoma. *The American Journal of Tropical Medicine and Hygiene* 75(1):108–111 DOI 10.4269/ajtmh.2006.75.108.
- Herrera LA, Ramirez T, Rodríguez U, Corona T, Sotelo J, Lorenzo M, Ramos F, Verdorfer I, Gebhart E, Ostrosky-Wegman P. 2000. Possible association between *Taenia solium* cysticercosis and cancer: increased frequency of DNA damage in peripheral lymphocytes from neurocysticercosis patients. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 94(1):61–65 DOI 10.1016/S0035-9203(00)90441-3.
- Hewitson JP, Grainger JR, Maizels RM. 2009. Helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity. *Molecular and Biochemical Parasitology* 167(1):1–11 DOI 10.1016/j.molbiopara.2009.04.008.
- Huang X, Zeng LR, Chen FS, Zhu JP, Zhu MH. 2018. *Trichuris suis* ova therapy in inflammatory bowel disease: a meta-analysis. *Medicine* 97(34):e12087 DOI 10.1097/MD.00000000000012087.
- Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1

- blockade. *Proceedings of the National Academy of Sciences of the United States of America* **99(19)**:12293–12297 DOI [10.1073/pnas.192461099](https://doi.org/10.1073/pnas.192461099).
- Kang YJ, Jo JO, Cho MK, Yu HS, Leem SH, Song KS, Ock MS, Cha HJ. 2013. *Trichinella spiralis* infection reduces tumor growth and metastasis of B16-F10 melanoma cells. *Veterinary Parasitology* **196(1–2)**:106–113 DOI [10.1016/j.vetpar.2013.02.021](https://doi.org/10.1016/j.vetpar.2013.02.021).
- Karadayi S, Arslan S, Sumer Z, Turan M, Sumer H, Karadayi K. 2013. Does hydatid disease have protective effects against lung cancer? *Molecular Biology Reports* **40(8)**:4701–4704 DOI [10.1007/s11033-013-2565-8](https://doi.org/10.1007/s11033-013-2565-8).
- Keir ME, Butte MJ, Freeman GJ, Sharpe AH. 2008. PD-1 and its ligands in tolerance and immunity. *Annual Review of Immunology* **26(1)**:677–704 DOI [10.1146/annurev.immunol.26.021607.090331](https://doi.org/10.1146/annurev.immunol.26.021607.090331).
- Ledesma-Soto Y, Callejas BE, Terrazas CA, Reyes JL, Espinoza-Jiménez A, González MI, León-Cabrera S, Morales R, Olgún JE, Saavedra R, Oghumu S, Satoskar AR, Terrazas LI. 2015. Extraintestinal helminth infection limits pathology and proinflammatory cytokine expression during DSS-induced ulcerative colitis: a role for alternatively activated macrophages and prostaglandins. *BioMed Research International* **2015(4)**:563425 DOI [10.1155/2015/563425](https://doi.org/10.1155/2015/563425).
- León-Cabrera S, Callejas BE, Ledesma-Soto Y, Coronel J, Pérez-Plasencia C, Gutiérrez-Cirlos EB, Ávila-Moreno F, Rodríguez-Sosa M, Hernández-Pando R, Marquina-Castillo B, Chirino YI, Terrazas LI. 2014. Extraintestinal helminth infection reduces the development of colitis-associated tumorigenesis. *International Journal of Biological Sciences* **10(9)**:948–956 DOI [10.7150/ijbs.9033](https://doi.org/10.7150/ijbs.9033).
- Maizels RM, Yazdanbakhsh M. 2003. Immune regulation by helminth parasites: cellular and molecular mechanisms. *Nature Reviews Immunology* **3(9)**:733–744 DOI [10.1038/nri1183](https://doi.org/10.1038/nri1183).
- Mamuti W, Sako Y, Nakao M, Xiao N, Nakaya K, Ishikawa Y, Yamasaki H, Lightowers MW, Ito A. 2006. Recent advances in characterization of Echinococcus antigen B. *Parasitology International* **55(Suppl 1)**:57–62 DOI [10.1016/j.parint.2005.11.008](https://doi.org/10.1016/j.parint.2005.11.008).
- Medeiros A, Chiribao ML, Ubillos L, Festari MF, Saldaña J, Robello C, Domínguez L, Calvete JJ, Osinaga E. 2008. Mucin-type O-glycosylation in *Mesocestoides vogae* (syn. corti). *International Journal for Parasitology* **38(3–4)**:265–276 DOI [10.1016/j.ijpara.2007.07.015](https://doi.org/10.1016/j.ijpara.2007.07.015).
- Mohammadi M, Spotin A, Mahami-Oskouei M, Shanebandi D, Ahmadpour E, Casulli A, Baghban A, Asadi M. 2021. MicroRNA-365 promotes apoptosis in human melanoma cell A375 treated with hydatid cyst fluid of *Echinococcus granulosus sensu stricto*. *Microbial Pathogenesis* **153**:104804 DOI [10.1016/j.micpath.2021.104804](https://doi.org/10.1016/j.micpath.2021.104804).
- Noya V, Bay S, Festari MF, García EP, Rodríguez E, Chiale C, Ganneau C, Baleux F, Astrada S, Bollati-Fogolín M, Osinaga E, Freire T. 2013. Mucin-like peptides from *Echinococcus granulosus* induce antitumor activity. *International Journal of Oncology* **43(3)**:775–784 DOI [10.3892/ijo.2013.2000](https://doi.org/10.3892/ijo.2013.2000).
- Oikonomopoulou K, Brinc D, Kyriacou K, Diamandis EP. 2013. Infection and cancer: reevaluation of the hygiene hypothesis. *Clinical Cancer Research* **19(11)**:2834–2841 DOI [10.1158/1078-0432.CCR-12-3661](https://doi.org/10.1158/1078-0432.CCR-12-3661).
- Oikonomopoulou K, Yu H, Wang Z, Vasiliou SK, Brinc D, Christofi G, Theodorou M, Pavlou P, Hadjisavvas A, Demetriou CA, Kyriacou K, Diamandis EP. 2016. Association between *Echinococcus granulosus* infection and cancer risk—a pilot study in Cyprus. *Clinical Chemistry and Laboratory Medicine* **54(12)**:1955–1961 DOI [10.1515/cclm-2016-0125](https://doi.org/10.1515/cclm-2016-0125).
- Olson PD, Yoder K, Fajardo L-GLF, Marty AM, van de Pas S, Olivier C, Relman DA. 2003. Lethal invasive cestodiasis in immunosuppressed patients. *The Journal of Infectious Diseases* **187(12)**:1962–1966 DOI [10.1086/375357](https://doi.org/10.1086/375357).

- Ou B, Cheng X, Xu Z, Chen C, Shen X, Zhao J, Lu A. 2019.** A positive feedback loop of β -catenin/CCR2 axis promotes regorafenib resistance in colorectal cancer. *Cell Death & Disease* **10(9)**:1–12 DOI [10.1038/s41419-019-1906-5](https://doi.org/10.1038/s41419-019-1906-5).
- Pérez-Torres A, Vera-Aguilera J, Hernaiz-Leonardo JC, Moreno-Aguilera E, Monteverde-Suarez D, Vera-Aguilera C, Estrada-Bárceñas D. 2013.** The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model. *Cancer Biotherapy & Radiopharmaceuticals* **28(9)**:682–690 DOI [10.1089/cbr.2012.1438](https://doi.org/10.1089/cbr.2012.1438).
- Piñón-Zárate G, Herrera-Enríquez MÁ, Hernández-Téllez B, Jarquín-Yáñez K, Castell-Rodríguez AE. 2014.** GK-1 improves the immune response induced by bone marrow dendritic cells loaded with MAGE-AX in mice with melanoma. *Journal of Immunology Research* **2014(2)**:158980 DOI [10.1155/2014/158980](https://doi.org/10.1155/2014/158980).
- Plumelle Y, Gonin C, Edouard A, Bucher BJ, Thomas L, Brebion A, Panelatti G. 1997.** Effect of *Strongyloides stercoralis* infection and eosinophilia on age at onset and prognosis of adult T-cell leukemia. *American Journal of Clinical Pathology* **107(1)**:81–87 DOI [10.1093/ajcp/107.1.81](https://doi.org/10.1093/ajcp/107.1.81).
- Rad SR, Daneshpour S, Mofid MR, Andalib A, Eskandariyan A, Darani HY. 2018.** Effect of hydatid cyst antigens on inhibition of melanoma cancer growth in mouse model. *Cellular and Molecular Biology* **64(12)**:1–5 DOI [10.14715/cmb/2018.64.12.1](https://doi.org/10.14715/cmb/2018.64.12.1).
- Ramos-Martínez E, Rojas-Serrano J, García-Hernández O, García-Vázquez FJ, Andrade WA, Avila G, Salinas-Pasquier L, López-Vancell MR. 2019.** The immune response to *Hymenolepis nana* in mice decreases tumorigenesis induced by 7,12 dimethylbenz-anthracene. *Cytokine* **123(1114–1124)**:154743 DOI [10.1016/j.cyto.2019.154743](https://doi.org/10.1016/j.cyto.2019.154743).
- Ranasinghe SL, Boyle GM, Fischer K, Potriquet J, Mulvenna JP, McManus DP. 2018.** Kunitz type protease inhibitor EgKI-1 from the canine tapeworm *Echinococcus granulosus* as a promising therapeutic against breast cancer. *PLOS ONE* **13(8)**:e0200433 DOI [10.1371/journal.pone.0200433](https://doi.org/10.1371/journal.pone.0200433).
- Ranasinghe SL, Fischer K, Zhang W, Gobert GN, McManus DP. 2015.** Cloning and characterization of two potent kunitz type protease inhibitors from *Echinococcus granulosus*. *PLOS Neglected Tropical Diseases* **9(12)**:e0004268 DOI [10.1371/journal.pntd.0004268](https://doi.org/10.1371/journal.pntd.0004268).
- Rashno Z, Rismani E, Ghasemi JB, Mansouri M, Shabani M, Afgar A. 2023.** Design of ion channel blocking, toxin-like Kunitz inhibitor peptides from the tapeworm, *Echinococcus granulosus*, with potential anti-cancer activity. *Scientific Reports* **13(1)**:11465 DOI [10.1038/s41598-023-38159-w](https://doi.org/10.1038/s41598-023-38159-w).
- Ribeiro Franco PI, do Carmo Neto JR, Miguel MP, Machado JR, Nunes Celes MR. 2023.** Cancer and *Trypanosoma cruzi*: tumor induction or protection? *Biochimie* **207**:113–121 DOI [10.1016/J.BIOCHI.2022.10.019](https://doi.org/10.1016/J.BIOCHI.2022.10.019).
- Rodríguez-Rodríguez N, Madera-Salcedo IK, Bugarin-Estrada E, Sánchez-Miranda E, Torres-García D, Cervantes-Torres J, Fragoso G, Rosetti F, Crispín JC, Sciutto E. 2020.** The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway. *Clinical Immunology* **212**:108240 DOI [10.1016/j.clim.2019.07.006](https://doi.org/10.1016/j.clim.2019.07.006).
- Rook GAW. 2010.** 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: darwinian medicine and the ‘hygiene’ or ‘old friends’ hypothesis. *Clinical and Experimental Immunology* **160(1)**:70–79 DOI [10.1111/j.1365-2249.2010.04133.x](https://doi.org/10.1111/j.1365-2249.2010.04133.x).
- Salagianni M, Baxevanis CN, Papamichail M, Perez SA. 2012.** New insights into the role of NK cells in cancer immunotherapy. *OncImmunology* **1(2)**:205–207 DOI [10.4161/onci.1.2.18398](https://doi.org/10.4161/onci.1.2.18398).
- Sauer S, Beinart D, Finn SMB, Kumar SL, Cheng Q, Hwang SE, Parker W, Devi GR. 2021.** *Hymenolepis diminuta*-based helminth therapy in C3(1)-TAg mice does not alter breast tumor

onset or progression. *Evolution, Medicine, and Public Health* 9(1):131–138
DOI 10.1093/emph/eoab007.

- Scholnik-Cabrera A, Juárez M, Oldak B, Cruz-Rivera M, Flisser A, Dueñas-González A, Buzoianu-Anguiano V, Orozco-Suarez S, Mendlovic F. 2020. *In vitro* employment of recombinant *Taenia solium* calreticulin as a novel strategy against breast and ovarian cancer stem-like cells. *Archives of Medical Research* 51(1):65–75 DOI 10.1016/j.arcmed.2019.12.003.
- Schiller JT, Lowy DR. 2021. An introduction to virus infections and human cancer. *Recent Results in Cancer Research* 217:1–11 DOI 10.1007/978-3-030-57362-1.
- Scholte LLS, Pascoal-Xavier MA, Nahum LA. 2018. Helminths and cancers from the evolutionary perspective. *Frontiers in Medicine* 5(4):16 DOI 10.3389/fmed.2018.00090.
- Schreiber M, Macháček T, Vajs V, Šmídová B, Majer M, Hrdý J, Tolde O, Brábek J, Rösel D, Horák P. 2024. Suppression of the growth and metastasis of mouse melanoma by *Taenia crassiceps* and *Mesocestoides corti* tapeworms. *Frontiers in Immunology* 15:1376907 DOI 10.3389/fimmu.2024.1376907.
- Sharafi SM, Rafiei R, Rafiei R, Hadipour M, Shirzad H, Khanahmad H, Darani HY. 2016. A nonglycosylated 27 KDa molecule as common antigen between human breast cancer and *Echinococcus granulosus* hydatid cyst wall. *Advances in Breast Cancer Research* 05(2):90–95 DOI 10.4236/abcr.2016.52010.
- Shepherd JC, Aitken A, McManus DP. 1991. A protein secreted *in vivo* by *Echinococcus granulosus* inhibits elastase activity and neutrophil chemotaxis. *Molecular and Biochemical Parasitology* 44(1):81–90 DOI 10.1016/0166-6851(91)90223-S.
- Springer GF. 1997. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. *Journal of Molecular Medicine* 75(8):594–602 DOI 10.1007/s001090050144.
- Strachan DP, Wickens K, Crane J, Pearce N, Beasley R. 2000. Family size, infection and atopy: the first decade of the “hygiene hypothesis” The magnitude of the effect of smaller family sizes on the increase in the prevalence of asthma and hay fever in the United Kingdom and New Zealand. *Thorax* 55(1):2–10 DOI 10.1136/thorax.55.suppl_1.S2.
- Terrazas LI, Bojalil R, Govezensky T, Larralde C. 1998. Shift from an early protective TH1-type immune response to a late permissive TH2-type response in murine cysticercosis (*Taenia crassiceps*). *The Journal of Parasitology* 84(1):74–81 DOI 10.2307/3284533.
- Torres-García D, Pérez-Torres A, Manoutcharian K, Orbe U, Servín-Blanco R, Frago G, Scitutto E. 2017. GK-1 peptide reduces tumor growth, decreases metastatic burden, and increases survival in a murine breast cancer model. *Vaccine* 35(42):5653–5661 DOI 10.1016/j.vaccine.2017.08.060.
- Turhan N, Esendagli G, Ozkayar O, Tunali G, Sokmensuer C, Abbasoglu O. 2015. Co-existence of *Echinococcus granulosus* infection and cancer metastasis in the liver correlates with reduced Th1 immune responses. *Parasite Immunology* 37(1):16–22 DOI 10.1111/pim.12152.
- Ubillos L, Medeiros A, Cancela M, Casaravilla C, Saldaña J, Domínguez L, Carmona C, Pendu J, Osinaga E. 2007. Characterization of the carcinoma-associated Tk antigen in helminth parasites. *Experimental Parasitology* 116(2):129–136 DOI 10.1016/j.exppara.2006.12.009.
- van Knapen F. 1980. *Echinococcus granulosus* infection and malignancy. *British Medical Journal* 281(6234):195–196 DOI 10.1136/bmj.281.6234.195.
- Vasilev S, Ilic N, Gruden-Movsesijan A, Vasilijic S, Bosic M, Sofronic-Milosavljevic L. 2015. Necrosis and apoptosis in *Trichinella spiralis*-mediated tumour reduction. *Central European Journal of Immunology* 40(1):42–53 DOI 10.5114/ceji.2015.50832.
- Vera-Aguilera J, Perez-Torres A, Beltran D, Villanueva-Ramos C, Wachtel M, Moreno-Aguilera E, Vera-Aguilera C, Ventolini G, Martínez-Zaguilán R, Sennoune SR. 2017. Novel

treatment of melanoma: combined parasite-derived peptide GK-1 and anti-programmed death ligand 1 therapy. *Cancer Biotherapy and Radiopharmaceuticals* 32(2):49–56
DOI 10.1089/cbr.2016.2123.

Walusimbi B, Lawson MAE, Nassuuna J, Kateete DP, Webb EL, Grecis RK, Elliott AM. 2023. The effects of helminth infections on the human gut microbiome: a systematic review and meta-analysis. *Frontiers in Microbiomes* 2:1174034 DOI 10.3389/frmbi.2023.1174034.

Wang XL, Fu BQ, Yang SJ, Wu XP, Cui GZ, Liu MF, Yu YL, Liu XY, Deng HK, Chen QJ, Liu MY. 2009. *Trichinella spiralis*-a potential anti-tumor agent. *Veterinary Parasitology* 159(3–4):249–252 DOI 10.1016/j.vetpar.2008.10.052.

Willms K, Zurabian R. 2010. *Taenia crassiceps*: in vivo and in vitro models. *Parasitology* 137(3):335–346 DOI 10.1017/S0031182009991442.

Wu Y, Duffey M, Alex SE, Suarez-Reyes C, Clark EH, Weatherhead JE. 2022. The role of helminths in the development of non-communicable diseases. *Frontiers in Immunology* 13:4713 DOI 10.3389/fimmu.2022.941977.

Yasen A, Wang M, Ran B, Lv G, Aji T, Xiao H, Shao Y, Wen H. 2021. *Echinococcus granulosus* protoscoleces promotes proliferation and invasion of hepatocellular carcinoma cells. *Cytotechnology* 73(1):13–22 DOI 10.1007/s10616-020-00437-0.

Yong WK, Heath DD, Savage T. 1979. Possible antigenic similarity between pulmonary carcinoma and cysts of *Echinococcus granulosus*. *British Medical Journal* 1(6176):1463–1464 DOI 10.1136/bmj.1.6176.1463-a.

Yousefi M, Akbari M, Hadipour M, Dehkordi AB, Farahbakhsh Z, Darani HY. 2023. Parasites as potential targets for cancer immunotherapy. *Journal of Cancer Research and Clinical Oncology* 149(10):8027–8038 DOI 10.1007/s00432-023-04694-2.

Zhang W, Ross AG, McManus DP. 2008. Mechanisms of immunity in hydatid disease: implications for vaccine development. *Journal of Immunology* 181(10):6679–6685 DOI 10.4049/jimmunol.181.10.6679.